Advanced Cell Diagnostics Competitors

Almost every factor that affects health – from genetics and the microbiome to disease and lifestyle – exerts its influence by altering metabolite levels in the body or other biological system. By producing the most accurate and comprehensive picture of the collection of metabolites, known as the metabolome, from a single biological sample, Metabolon can deliver an instantaneous snapshot of the entire physiology of a living being at a discreet point in time, as well as identify changes in that system brought about the impact of disease, medical intervention, diet or the environment. This deep and comprehensive view of the metabolome provides biological insights that cannot be revealed through any other research methodology, enabling life sciences researchers and drug developers to discover answers some of biology’s most difficult questions. Metabolon's unrivaled capability to look deep into the metabolome has enabled us to build the world’s largest library of compounds that currently includes 5,200+ total known molecules. Our proprietary Precision Metabolomics™ platform, combined with the world's most experienced metabolomics scientists, delivers biologic insights and identification of novel commercial opportunities for drug discovery and development, through clinical trials and life cycle management. Metabolon’s expertise is also accelerating research and product development for clients in academia, population health, consumer products, and nutrition industries. Founded in 2000 and based in Research Triangle Park, North Carolina, Metabolon has conducted more than 10,000 independent and collaborative studies, resulting in 2,000+ publications in leading peer-reviewed journals. For more information about our technology, products and services, please visit www.metabolon.com.

BioGenex designs, develops, and commercializes advanced fully-automated molecular pathology systems for cancer diagnosis, prognosis, personalized medicine, and life science research. The recent introduction of our eFISHency integrated workflow solution for FISH laboratories and miRNA system for characterization of cancer of unknown primary (CUP) and for undifferentiated tumors is a game changer that has no rival in the industry. Our fully automated molecular pathology work stations are the most advanced system globally. Our customer focused approach, with premier after sales support and excellent technical service, provides the best in class customer care. Our spirit of innovation drives us to deliver cutting edge technology, years ahead of our competition, and the finest systems for life science research and diagnostics. With a team of accomplished technical, business and customer support professionals, BioGenex strives to reach the pinnacle of the global molecular medicine industry by offering cost-effective solutions for life sciences research and personalized medicine. Additionally, the partnership of BioGenex with top-notch universities, hospitals, and the pharmaceutical and biotechnology industry drives its innovative research and product development activities. The company is also known for its pre- and post-sales customer support that complements the high quality products and solutions offered by the firm.

Biocept, Inc. (Nasdaq: BIOC) develops and performs clinical laboratory tests to help patients with cancer that has metastasized to the central nervous system (CNS). Our CNSide™ assay provides enhanced detection and analysis of tumor cells and cell-free DNA from cerebrospinal fluid (CSF). Quantitative results help evaluate a patient’s response to treatment. Additional biomarkers can characterize genetic changes associated with therapy resistance and identify new options for treating CNS metastasis. CNSide results from Biocept’s CLIA-certified and CAP-accredited laboratory help oncologists manage one of the most difficult complications of cancer, answering three critical questions: Is there tumor in the CSF? Is there a target for treatment? Is there a trend in treatment response? The Biocept team is dedicated to improving care for cancer patients – which means making a difference in people’s lives, every day. Biocept also provides RT-PCR based COVID-19 testing to support state and national public health efforts.